Tarsus Pharmaceuticals Inc Forecast, price target & analysts
Tarsus Pharmaceuticals Inc Target price 2025 - Analyst rating & recommendation
Tarsus Pharmaceuticals Inc Classifications & Recommendation:
Tarsus Pharmaceuticals Inc Price Target
| Target Price | $86.70 |
| Price | $75.64 |
| Potential |
14.62%
register free of charge
|
| Number of Estimates | 9 |
|
9 Analysts have issued a price target Tarsus Pharmaceuticals Inc 2026 .
The average Tarsus Pharmaceuticals Inc target price is $86.70.
This is
14.62%
register free of charge
$92.40
22.16%
register free of charge
$45.45
39.91%
register free of charge
|
|
| A rating was issued by 14 analysts: 12 Analysts recommend Tarsus Pharmaceuticals Inc to buy, 2 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Tarsus Pharmaceuticals Inc stock has an average upside potential 2026 of
14.62%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 182.95 | 438.10 |
| 948.42% | 139.46% | |
| EBITDA Margin | -65.23% | -10.18% |
| 92.00% | 84.39% | |
| Net Margin | -63.16% | -15.52% |
| 91.89% | 75.43% |
9 Analysts have issued a sales forecast Tarsus Pharmaceuticals Inc 2025 . The average Tarsus Pharmaceuticals Inc sales estimate is
This results in the following potential growth metrics:
4 Analysts have issued an Tarsus Pharmaceuticals Inc EBITDA forecast 2025. The average Tarsus Pharmaceuticals Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
10 Tarsus Pharmaceuticals Inc Analysts have issued a net profit forecast 2025. The average Tarsus Pharmaceuticals Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2032
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -3.07 | -1.60 |
| 33.55% | 47.88% | |
| P/E | negative | |
| EV/Sales | 6.58 |
10 Analysts have issued a Tarsus Pharmaceuticals Inc forecast for earnings per share. The average Tarsus Pharmaceuticals Inc EPS is
This results in the following potential growth metrics and future valuations:
Tarsus Pharmaceuticals Inc...
Current Tarsus Pharmaceuticals Inc Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Guggenheim |
Locked
➜
Locked
|
Locked | Nov 05 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Oct 20 2025 |
| Goldman Sachs |
Locked
➜
Locked
|
Locked | May 05 2025 |
| Guggenheim |
Locked
➜
Locked
|
Locked | May 02 2025 |
| Jefferies |
Locked
➜
Locked
|
Locked | Mar 06 2025 |
| Barclays |
Locked
➜
Locked
|
Locked | Feb 26 2025 |
| Guggenheim |
Locked
➜
Locked
|
Locked | Feb 26 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Guggenheim:
Locked
➜
Locked
|
Nov 05 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Oct 20 2025 |
|
Locked
Goldman Sachs:
Locked
➜
Locked
|
May 05 2025 |
|
Locked
Guggenheim:
Locked
➜
Locked
|
May 02 2025 |
|
Locked
Jefferies:
Locked
➜
Locked
|
Mar 06 2025 |
|
Locked
Barclays:
Locked
➜
Locked
|
Feb 26 2025 |
|
Locked
Guggenheim:
Locked
➜
Locked
|
Feb 26 2025 |
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
